07-631
Anti-cdk2 Antibody
Upstate®, from rabbit
Synonym(s):
Anti-CDKN2, Anti-p33(CDK2)
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Clone:
polyclonal
Species reactivity:
human
Application:
IP, WB
Citations:
18
Quality Level
biological source
rabbit
conjugate
unconjugated
antibody form
purified antibody
antibody product type
primary antibodies
clone
polyclonal
species reactivity
human
manufacturer/tradename
Upstate®
technique(s)
immunoprecipitation (IP): suitable, western blot: suitable
isotype
IgG
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... CDK2AP1(8099)
General description
33 kDa
Immunogen
peptide corresponding to amino acids 287-298 (C-QDVTKPVPHLRL) of human cdk2
Application
Anti-cdk2 Antibody is a high quality Rabbit Polyclonal Antibody for the detection of cdk2 & has been validated in IP & WB.
Biochem/physiol Actions
Predicted to cross-react with mouse, rat, non-human primates, and hamster based on sequence homology
Recognizes human p33cdk2 protein kinase.
Physical form
Format: Purified
Analysis Note
Control
Colon tissue
Colon tissue
routinely evaluated by immunoblot in nuclear extracts from HeLa cells
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Try our Product Selector Tool to narrow your options
Storage Class
10 - Combustible liquids
wgk
WGK 1
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Carlotta Costa et al.
Cancer discovery, 10(1), 72-85 (2019-10-09)
The combination of CDK4/6 inhibitors with antiestrogen therapies significantly improves clinical outcomes in ER-positive advanced breast cancer. To identify mechanisms of acquired resistance, we analyzed serial biopsies and rapid autopsies from patients treated with the combination of the CDK4/6 inhibitor
Sublytic complement attack induces cell cycle in oligodendrocytes.
Rus, H G, et al.
Journal of immunology (Baltimore, Md. : 1950), 156, 4892-4900 (1996)
Sonya Hui et al.
Circulation research, 108(9), 1053-1062 (2011-03-05)
Cell cycle progression in vascular smooth muscle cells (VSMCs) is a therapeutic target for restenosis. Having discovered that calmodulin (CaM)-dependent cyclin E/CDK2 activity underlies Ca(2+)-sensitive G(1)-to-S phase transitions in VSMCs, we sought to explore the physiological importance of the CaM-cyclin
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 07-631 | 04053252369995 |